When the New β-Lactam/β-Lactamase Inhibitors Aren’t Enough
Asundexian for Secondary Stroke Prevention OCEANIC-STROKE — A Three-Lens Critical Appraisal
OCEANIC-STROKE met its primary endpoint with a 26% relative reduction in ischemic stroke and no excess major bleeding — but the prespecified hierarchy broke at the 90-day endpoint. A statistician, a neurologist, and a researcher walk into a journal club. Here's what they each see.
Beyond Weight Loss: Reading the GLP-1 Side Effect Profile in Real Numbers A field guide for clinicians who are tired of being shown hazard ratios without denominators.
The Aspiration Anaerobe Myth What actually colonizes the aerodigestive tract — and why reflexive Zosyn for “possible aspiration” fails basic microbiology
Flecainide After PCI: 35 Years After CAST, Is It Time to Reconsider Class Ic Antiarrhythmics in Coronary Artery Disease?
Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Surviving Sepsis Campaign 2026: A Comprehensive Pharmacotherapy Review
The SSC 2026 Guidelines represent the most comprehensive sepsis update since 2021 — with major changes to antibiotic selection, vasopressor targets, fluid resuscitation, and a new strong recommendation for prolonged beta-lactam infusion.
Time of Death: Diphenhydramine — A Pharmacist's Case for Abandoning a Relic of 20th-Century Medicine
Diphenhydramine has occupied American medicine for over 70 years. A pharmacologist with 30 years of clinical experience makes the case that it's time to stop prescribing out of habit and start prescribing based on evidence.
Rethinking C. diff Treatment: Is Fidaxomicin Worth the Money?
The TAPER-V trial forces us to ask a question we should have been asking all along — would fidaxomicin have demonstrated superiority if the original trials had used longer follow-up?
2026 ACC/AHA Dyslipidemia Guideline: A Comprehensive Pharmacotherapy Review
The 2026 ACC/AHA Dyslipidemia Guideline represents the most significant overhaul of lipid management since 2018 — introducing specific cholesterol targets and an expanded pharmacotherapeutic armamentarium.